2023
Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens
Fang Z, Monteiro V, Renauer P, Shang X, Suzuki K, Ling X, Bai M, Xiang Y, Levchenko A, Booth C, Lucas C, Chen S. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Research 2023, 33: 407-410. PMID: 36879038, PMCID: PMC9988199, DOI: 10.1038/s41422-023-00792-5.Peer-Reviewed Original Research
2022
No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination
Lu-Culligan A, Tabachnikova A, Pérez-Then E, Tokuyama M, Lee HJ, Lucas C, Monteiro V, Miric M, Brache V, Cochon L, Muenker MC, Mohanty S, Huang J, Kang I, Dela Cruz C, Farhadian S, Campbell M, Yildirim I, Shaw AC, Ma S, Vermund SH, Ko AI, Omer SB, Iwasaki A. No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination. PLOS Biology 2022, 20: e3001506. PMID: 35609110, PMCID: PMC9129011, DOI: 10.1371/journal.pbio.3001506.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinationMRNA vaccinationEarly pregnancyFetal sizeCoronavirus disease 2019 (COVID-19) mRNA vaccinationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Maternal antibody statusAdverse neonatal outcomesSyndrome coronavirus 2Birth defectsPolyinosinic-polycytidylic acidCrown-rump lengthGross birth defectsUnvaccinated adultsMaternal illnessNeonatal outcomesVaccinated adultsAntibody statusTLR3 agonistEarly immunizationMurine pregnancyAntibody inductionCoronavirus 2
2021
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
Mao T, Israelow B, Lucas C, Vogels CBF, Gomez-Calvo ML, Fedorova O, Breban MI, Menasche BL, Dong H, Linehan M, Alpert T, Anderson F, Earnest R, Fauver J, Kalinich C, Munyenyembe K, Ott I, Petrone M, Rothman J, Watkins A, Wilen C, Landry M, Grubaugh N, Pyle A, Iwasaki A. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. Journal Of Experimental Medicine 2021, 219: e20211818. PMID: 34757384, PMCID: PMC8590200, DOI: 10.1084/jem.20211818.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionChronic SARS-CoV-2 infectionVariants of concernLethal SARS-CoV-2 infectionPost-infection therapyLower respiratory tractPost-exposure treatmentType I interferonSARS-CoV-2Effective medical countermeasuresAdaptive immune systemBroad-spectrum antiviralsContext of infectionSingle doseRespiratory tractViral controlImmunodeficient miceSevere diseaseMouse modelI interferonViral infectionImmune systemInnate immunityDisease preventionConsiderable efficacy
2018
Critical role of CD4+ T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection
Lucas CGO, Kitoko JZ, Ferreira FM, Suzart VG, Papa MP, Coelho SVA, Cavazzoni CB, Paula-Neto HA, Olsen PC, Iwasaki A, Pereira RM, Pimentel-Coelho PM, Vale AM, de Arruda LB, Bozza MT. Critical role of CD4+ T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection. Nature Communications 2018, 9: 3136. PMID: 30087337, PMCID: PMC6081430, DOI: 10.1038/s41467-018-05519-4.Peer-Reviewed Original ResearchConceptsT cellsZika virusMurine adoptive transfer modelParticipation of CD4Adoptive transfer modelT cell responsesImportance of CD4Protective adaptive immunityRapid disease onsetZika virus infectionFuture vaccine designAntibody-mediated resistanceCytotoxic CD8Viral loadZIKV infectionAntibody responsePrimary infectionRecipient miceDisease onsetVirus infectionProtective effectAdaptive immunityIFNγ signalingCD4B lymphocytes
2016
Dendritic cells primed with a chimeric plasmid containing HIV‐1‐gag associated with lysosomal‐associated protein‐1 (LAMP/gag) is a potential therapeutic vaccine against HIV
Lucas C, Matassoli F, Peçanha L, Santillo B, da Silva Oliveira L, Oshiro T, Marques E, Oxenius A, de Arruda L. Dendritic cells primed with a chimeric plasmid containing HIV‐1‐gag associated with lysosomal‐associated protein‐1 (LAMP/gag) is a potential therapeutic vaccine against HIV. The FASEB Journal 2016, 30: 2970-2984. PMID: 27199296, DOI: 10.1096/fj.201500059.Peer-Reviewed Original ResearchConceptsT cell responsesPotential therapeutic vaccineDendritic cellsTherapeutic vaccinesT cellsImmune responseHIV-specific cellular immune responsesGreater T cell responsesPotential of DCUpregulation of CD38Human dendritic cellsCellular immune responsesProtein 1Immunization of miceMouse dendritic cellsTNF-α productionHIV infectionAntibody levelsHLA-DRVaccine efficacyDNA vaccineT lymphocytesGranzyme BImmune functionVaccine vehicle
2015
Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus
Medaglia M, Moussatché N, Nitsche A, Dabrowski P, Li Y, Damon I, Lucas C, Arruda L, Damaso C. Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus. Journal Of Virology 2015, 89: 11909-11925. PMID: 26378174, PMCID: PMC4645304, DOI: 10.1128/jvi.01833-15.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsBase SequenceBayes TheoremBiological EvolutionBrazilCell LineComet AssayEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueHumansImmunoglobulin GMiceMice, Inbred BALB CModels, GeneticMolecular Sequence DataPhylogenySequence Analysis, DNASmallpoxSpecies SpecificityVaccinia virusViral VaccinesVirulenceVirulence FactorsConceptsFirst-generation vaccinesSmallpox vaccineSecond-generation smallpox vaccineVaccine strainNew-generation smallpox vaccinesVaccinia virusProtective immune responseIntensive vaccination programsImmunological featuresInfected miceHealth care standardsImmune protectionVaccination programLethal infectionImmune responseVACV strainVaccineCare standardsSmallpox eradication programmeLow virulenceAdverse effectsVACVLow pathogenicitySmallpox eradicationVaccine producers